Skip to Content
Merck
  • Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.

Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.

Bioorganic & medicinal chemistry (2010-02-27)
Francisco J Prado-Prado, Xerardo García-Mera, Humberto González-Díaz
ABSTRACT

There are many of pathogen parasite species with different susceptibility profile to antiparasitic drugs. Unfortunately, almost QSAR models predict the biological activity of drugs against only one parasite species. Consequently, predicting the probability with which a drug is active against different species with a single unify model is a goal of the major importance. In so doing, we use Markov Chains theory to calculate new multi-target spectral moments to fit a QSAR model that predict by the first time a mt-QSAR model for 500 drugs tested in the literature against 16 parasite species and other 207 drugs no tested in the literature using spectral moments. The data was processed by linear discriminant analysis (LDA) classifying drugs as active or non-active against the different tested parasite species. The model correctly classifies 311 out of 358 active compounds (86.9%) and 2328 out of 2577 non-active compounds (90.3%) in training series. Overall training performance was 89.9%. Validation of the model was carried out by means of external predicting series. In these series the model classified correctly 157 out 190, 82.6% of antiparasitic compounds and 1151 out of 1277 non-active compounds (90.1%). Overall predictability performance was 89.2%. In addition we developed four types of non Linear Artificial neural networks (ANN) and we compared with the mt-QSAR model. The improved ANN model had an overall training performance was 87%. The present work report the first attempts to calculate within a unify framework probabilities of antiparasitic action of drugs against different parasite species based on spectral moment analysis.

MATERIALS
Product Number
Brand
Product Description

Supelco
Sulfadoxin, VETRANAL®, analytical standard
Sigma-Aldrich
Trimethoprim, ≥99.0% (HPLC)
Sigma-Aldrich
L-Ascorbic acid, 99%
Supelco
Trimethoprim, VETRANAL®, analytical standard
Sigma-Aldrich
Phenacetin, ≥98.0% (HPLC)
Supelco
L-Ascorbic acid, analytical standard
Sigma-Aldrich
Decyl β-D-glucopyranoside, ≥98% (GC)
Sigma-Aldrich
Ibuprofen, ≥98% (GC)
Sigma-Aldrich
Acetohydroxamic acid, 98%
Sigma-Aldrich
L-Ascorbic acid, puriss. p.a., ≥99.0% (RT)
Sigma-Aldrich
Erythromycin, tested according to Ph. Eur.
Sigma-Aldrich
Cinchonine, crystallized, ≥98.0% (NT)
Sigma-Aldrich
D-Mannitol, tested according to Ph. Eur.
Sigma-Aldrich
L-Ascorbic acid, ACS reagent, ≥99%
Sigma-Aldrich
Benzhydroxamic acid, 99%
Sigma-Aldrich
O-Tritylhydroxylamine, 95%
Sigma-Aldrich
L-Ascorbic acid, reagent grade
Sigma-Aldrich
3-(N,N-Dimethylpalmitylammonio)propanesulfonate, ≥98% (TLC)
Sigma-Aldrich
L-Ascorbic acid, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
L-Ascorbic acid, reagent grade, crystalline
Sigma-Aldrich
L-Ascorbic acid, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
Leuprolide acetate salt, ≥98% (HPLC)
Sigma-Aldrich
Cytosine β-D-arabinofuranoside, crystalline, ≥90% (HPLC)
Sigma-Aldrich
Nifedipine, ≥98% (HPLC), powder
Sigma-Aldrich
Erythromycin, meets USP testing specifications
Supelco
Fluocinolone acetonide, analytical standard
Sigma-Aldrich
Erythromycin, potency: ≥850 μg per mg
Sigma-Aldrich
Lidocaine, analytical standard
Sigma-Aldrich
Lidocaine, powder
Sigma-Aldrich
Phenylbutazone